Extended indication Extension of indication to include new therapeutic indication in adolescents aged 12 to 17 years for the treatment of moderate to severe major depress
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Agomelatine
Domain Neurological disorders
Reason of inclusion Indication extension IND
Main indication Depression
Extended indication Extension of indication to include new therapeutic indication in adolescents aged 12 to 17 years for the treatment of moderate to severe major depressive episodes, if depression is unresponsive to psychological therapy alone.
Proprietary name Valdoxan
Manufacturer Servier
Mechanism of action Receptor agonist
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional remarks selectieve en specifieke agonist van de melatonine receptoren MT1 en MT2

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date October 2022
Expected Registration September 2023
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Duration of treatment Average 12 week / weeks
Frequency of administration 1 times a day
Dosage per administration 25 mg
References EudraCT, 2015-002181-23

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information